Bioavailablility of rifampicin in a separate formulation and fixed dose combination with iosniased NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis

Abstract
No Central African Journal of Medicine Vol. 45 (6) 1999: pp. 141-143